



Updates: Office of Infectious Disease and HIV/AIDS Policy

June 18, 2021



Division of Vaccines
Office of Infectious Disease and HIV/AIDS Policy
Office of the Assistant Secretary for Health

National Vaccine Advisory Committee

- **Met on June 16–17, 2021**
- **Updates from Vaccine Confidence and Immunization Equity Subcommittees; vote on immunization equity report**
- **Catch up vaccinations for adults and adolescents**
- **Update on COVID-19 vaccines**
 - **Vaccine safety updates**
 - **Implications for variants**
 - **Authorizations for use**
- **Next meeting TBD**



National Vaccine Plan 2021–2025 Implementation

- **Vaccines National Strategic Plan 2021–2025 released on January 19**
- **5 overarching goals**
 - **Vaccine innovation**
 - **Vaccine safety**
 - **Vaccine confidence**
 - **Access to vaccines**
 - **Global collaboration**
- **Implementation plan to be developed in collaboration with federal partners**



Vaccine Safety Report

- **AHRQ released updated systematic review of adverse events associated with routinely recommended vaccines on May 25**
- **Literature review through November 9, 2020; plus trial registries, other materials**
- **Reviewed observed rates, relative risks for key adverse events; assessed strength of evidence**
- **Included new vaccines since 2014 (e.g., recombinant and adjuvanted influenza vaccines, recombinant zoster vaccine, hepatitis B vaccine with novel adjuvant)**
- **Does not include COVID-19 vaccines**



Vaccine Safety Report (2)

- **Outcomes: adverse events identified in participants (for pregnant women, in fetuses and infants); presence or absence of harms, toxicities, transient side effects, adverse health outcomes**
- **Key adverse events: cardiovascular events, autoimmune disease, Guillain-Barre syndrome, seizures, anaphylaxis, idiopathic thrombocytopenic purpura, reproductive system events, death**
- **Timing of outcomes: short = 30–42 days after vaccination, long = >42 days after vaccination**



Vaccine Safety Report (3)

- Screened 56,608 citations, reviewed 338 studies in 518 publications
- No new evidence of increased risk for key adverse events for adults, children, pregnant people
- Safety signals from prior reports (e.g., anaphylaxis, febrile seizures) remain unchanged for children and adults
- No evidence of increased adverse events in pregnant people
- Insufficient data for some rare potential adverse events
- <https://effectivehealthcare.ahrq.gov/products/safety-vaccines/research>





**Office of Infectious Disease and HIV/AIDS Policy
Office of the Assistant Secretary for Health
Department of Health and Human Services**

**WWW.VACCINES.GOV
WWW.HHS.GOV/VACCINES
WWW.HHS.GOV/OIDP
[@HHSVACCINES](https://twitter.com/HHSVACCINES)**